Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Herman, James G.

University Of Pittsburgh At Pittsburgh
United States

Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignancies 5U2CCA271885-04 Wendy Wang, Ph.D., M.Sc.
Herrmann, Joerg

Mayo Clinic Rochester
United States

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial 5R01CA233610-06 Eileen Dimond, R.N., M.S.
Herrmann, Joerg

Mayo Clinic Rochester
United States

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial 5R01CA233610-06 Eileen Dimond, R.N., M.S.
Hilakivi-Clarke, Leena A.

University Of Minnesota
United States

Effect of maternal obesity on breast cancer among offspring: role of the gut microbiota 5R01CA276775-03 Amit Kumar, Ph.D.
Hill, Joshua Aiden

Fred Hutchinson Cancer Center
United States

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy 5R01CA276040-03 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Hitchins, Megan P

H. Lee Moffitt Cancer Ctr & Res Inst
United States

Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age 7R01CA252042-05 Matthew Young, Ph.D.
Hollingsworth, Michael A.

University Of Nebraska Medical Center
United States

Pancreatic Cancer Detection Consortium 5U01CA210240-09 Matthew Young, Ph.D.
Hoshida, Yujin

Ut Southwestern Medical Center
United States

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis 4U01CA288375-03 Sidney Fu, M.D.
Houghton, A Mcgarry

Fred Hutchinson Cancer Center
United States

Tumor-specific autoantibodies for SCLC early detection 5R01CA243328-06 Guillermo Marquez, Ph.D.
Howitt, Brooke E

Stanford University
United States

Unraveling heterogeneity in endometrial cancer via integrated single cell genotype-phenotype mapping 1R37CA303960-01 Goli Samimi, Ph.D., M.P.H.
Hruska, Carrie B

Mayo Clinic Rochester
United States

Density MATTERS Clinical Trial 5R01CA239200-05 Claire Zhu, Ph.D.
Hsu, Li

Fred Hutchinson Cancer Center
United States

Statistical Methods for Precision Prevention 1R01CA297681-01 Claire Zhu, Ph.D.
Hu, Shuiying

Ohio State University
United States

Targeting neuronal transport to ameliorate vincristine neurotoxicity 5R01CA272254-03 Rachel Altshuler, Ph.D.
Hu, Jim

Weill Medical Coll Of Cornell Univ
United States

Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) 5R01CA259173-04 Marjorie Perloff, M.D.
Hu, Shuiying

Ohio State University
United States

Targeting neuronal transport to ameliorate vincristine neurotoxicity 5R01CA272254-03 Rachel Altshuler, Ph.D.